WHAT IS CLAIMED IS:

1	1. A method for prophylaxis or treatment of breast cancer in a
2	mammalian patient comprising administering to said patient a therapeutically effective
3	amount of one or more compound(s) selected from the group consisting of carbetocin and
4	other long-acting oxytocin analogues in a pharmaceutically acceptable carrier sufficient to
5	inhibit initiation or growth of breast cancer in said patient.

- 2. The method of claim 1, wherein said one or more oxytocin analogue(s) comprises carbetocin.
- 3. The method of claim 1, wherein said one or more oxytocin analogue(s) is/are administered to said patient by a mode of administration selected from intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, or transdermal delivery.
- 4. The method of claim 3, wherein said one or more oxytocin analogue(s) is/are administered to said patient intranasally.
- 5. The method of claim 3, wherein said one or more oxytocin analogue(s) is/are formulated in said carrier for intranasal or intrapulmonary administration.
- 1 6. The method of claim 5, wherein said one or more oxytocin 2 analogue(s) is/are formulated in a powder or aqueous formulation for intranasal delivery.
 - 7. The method of claim 6, wherein said one or more oxytocin analogue(s) is/are combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal delivery.
 - 8. The method of claim 6, wherein said carbetocin is formulated with a nonionic surfactant and polysorbate-80 in an aqueous formulation for intranasal delivery.

3

administration.

_				
1	9. The method of claim 1, wherein said one or more oxytocin			
2	analogue(s) is/are administered in a dose of at least one microgram.			
1	The method of claim 1, wherein said one or more oxytocin			
2	analogue(s) is/are administered daily in an intranasal formulation.			
2	analogue(s) is/are administered daily in an intraliasar formulation.			
1	11. The method of claim 1, further comprising administering			
2	tamoxifen and/or raloxifene to said patient in an amount sufficient to inhibit initiation or			
3	growth of estrogen-dependent breast cancer in said patient.			
1	12. The method of claim 11, wherein said one or more oxytocin			
2	analogue(s) and said tamoxifen and/or raloxifene are administered simultaneously as a			
3	mixture.			
1	13. A method for prophylaxis or treatment of a psychiatric disorder in			
2				
	a mammalian patient comprising administering to said patient a therapeutically effective			
3	amount of one or more compound(s) selected from the group consisting of carbetocin and			
4	other long-acting oxytocin analogues in a pharmaceutically acceptable carrier sufficient to			
5	alleviate an obsessive-compulsive behavior of said disorder in said patient.			
1	14. The method of claim 13, wherein said psychiatric disorder is			
2	obsessive compulsive disorder, Praeder Willi syndrome or autism.			
1	15. The method of claim 13, wherein said one or more oxytocin			
2	analogue(s) comprises carbetocin.			
1	16. The method of claim 13, wherein said one or more oxytocin			
2	analogue(s) is/are administered to said patient by a mode of administration selected from			
3	intramuscular, intravenous, intranasal, intrapulmonary, subcutaneous, parenteral, oral, and			
4	transdermal delivery.			
1	17. The method of claim 16, wherein said one or more oxytocin			
2	analogue(s) is/are administered to said patient intranasally.			
1				
1	18. The method of claim 16, wherein said one or more oxytocin			
2	analogue(s) is/are formulated in said carrier for intranasal or intrapulmonary			

patient.

6

1	19. The method of claim 18, wherein said one or more oxytocin		
2	analogue(s) is/are formulated in a powder or aqueous formulation for intranasal delivery.		
1	20. The method of claim 19, wherein said one or more oxytocin		
2	analogue(s) is/are combined in an aqueous formulation with one or more excipients		
3	selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-		
4	9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl		
5	paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal		
6	delivery.		
1	21. The method of claim 19, wherein said carbetocin is formulated		
2	with a nonionic surfactant and polysorbate-80 in an aqueous formulation for intranasal		
3	delivery.		
1	22. The method of claim 13, wherein said one or more oxytocin		
2	analogue(s) is/are administered in a dose of at least one microgram.		
1	The method of claim 13, wherein said one or more oxytocin		
2	analogue(s) is/are administered daily in an intranasal formulation.		
1	24. The method of claim 13, further comprising administering a		
2	selective serotonin reuptake inhibitor or serotonin reuptake inhibitor to said patient in an		
3	amount sufficient to alleviate an obsessive-compulsive behavior in said patient.		
1	25. The method of claim 24, wherein said one or more oxytocin		
2	analogue(s) and said selective serotonin reuptake inhibitor are administered		
3	simultaneously as a mixture.		
1	26. A pharmaceutical composition for prophylaxis or treatment of		
2	breast cancer in a mammalian patient comprising a therapeutically effective amount of		
3	one or more oxytocin analogue(s) selected from the group consisting of carbetocin and		
4	other long-acting oxytocin analogues in a pharmaceutically acceptable carrier, wherein		
5	said composition is sufficient to inhibit initiation or growth of breast cancer in said		

1	27.	The pharmaceutical composition of claim 26, wherein said one or			
2	more oxytocin analogue(s) comprises carbetocin.				
1	28.	The pharmaceutical composition of claim 26, wherein said one or			
2	more oxytocin analogue(s) is/are formulated in said carrier for intranasal or				
3	intrapulmonary administration.				
1	29	The pharmaceutical composition of claim 26, wherein said one or			

- 29. The pharmaceutical composition of claim 26, wherein said one or more oxytocin analogue(s) is/are formulated in a powder or aqueous formulation for intranasal delivery.
- 30. The pharmaceutical composition of claim 26, wherein said one or more oxytocin analogue(s) is/are combined in an aqueous formulation with one or more excipients selected from the group consisting of nonoxynol-9, laureth-9, poloxamer-124, octoxynol-9, lauramide DEA, chlorobutanol, glycerol, citric acid, sodium phosphate, methyl paraben, propyl paraben, sorbitol, sodium chloride, and/or sodium acetate for intranasal delivery.
- 31. The pharmaceutical composition of claim 26, prepared in a unit dosage form containing at least one microgram of said one or more oxytocin analogue(s).
- 32. The pharmaceutical composition of claim 26, further comprising tamoxifen and/or raloxifen in an amount sufficient to inhibit initiation or growth of estrogen-dependent breast cancer in said patient.
- 33. A medicament suspension or powder for nasal administration to treat or prevent breast cancer comprising carbetocin and a powder of one or more cation exchange resins and/or one or more adsorbent resins.
- 34. A pharmaceutical composition for prophylaxis or treatment of a psychiatric disorder in a mammalian patient comprising a therapeutically effective amount of one or more oxytocin analogue(s) selected from the group consisting of carbetocin and other long-acting oxytocin analogues in a pharmaceutically acceptable carrier, wherein said composition is sufficient to alleviate at least one symptom of said psychiatric disorder in said patient.

1	35.	The pharmaceutical composition of claim 34, wherein said one or	
2	more oxytocin analogue(s) comprises carbetocin.		
1	36.	The pharmaceutical composition of claim 34, wherein said one or	
2	more oxytocin analogue(s) is/are formulated in said carrier for intranasal or		
3	intrapulmonary administration.		
1	37.	The pharmaceutical composition of claim 34, wherein said one or	
2	more oxytocin analogue(s) is/are formulated in a powder or aqueous formulation for		
3	intranasal delivery.		
1	38.	The pharmaceutical composition of claim 34, further comprising a	
2	selective serotonin re	euptake inhibitor or serotonin reuptake inhibitor.	